Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for 4D Molecular Therapeutics (NASDAQ: FDMT) over the past three months, with a recent trend towards somewhat bullish sentiments. The average 12-month price target has decreased from $42.60 to $38.0. Key analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Despite a significant decline in revenue growth and negative net margins, the company shows strong ROE and ROA, and maintains a low debt-to-equity ratio.
July 18, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed ratings for 4D Molecular Therapeutics (NASDAQ: FDMT) with a recent trend towards somewhat bullish. The average 12-month price target has decreased from $42.60 to $38.0. Despite a significant decline in revenue growth and negative net margins, the company shows strong ROE and ROA, and maintains a low debt-to-equity ratio.
The mixed analyst ratings and recent trend towards somewhat bullish sentiments indicate a neutral short-term impact on FDMT's stock price. The decrease in the average price target suggests some caution among analysts. However, the company's strong ROE and ROA, along with a low debt-to-equity ratio, provide a positive outlook, balancing the negative impact of declining revenue growth and net margins.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100